Instituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo y Enfermedades Metabolicas

Academic/Hospital

Also known as: Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. | Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. | Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-AGS)

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

Nov 1, 2011

Last known activity

May 31, 2022

Timeline

No events for the selected filters.

Drugs by trial phase (11 distinct, 6 trials)

Phase 4 (1 own, 0 via acquisition)

escherichia coli nissle 1917

Phase 3 (7 own, 0 via acquisition)

Phase 2 (1 own, 0 via acquisition)

ivermectin

Phase 1 (2 own, 0 via acquisition)

Indications

Studied for

Recent trials (7)

NCT05324059OfficialPhase 3May 31, 2022
NCT05324059Overall official - principal investigatorPhase 3May 31, 2022
NCT04927299Overall official - principal investigatorPhase 3Jun 30, 2021
NCT04882293Overall official - principal investigatorPhase 3Jun 30, 2021
NCT04407507Lead sponsorPhase 2Jun 30, 2020
NCT04895059Overall official - principal investigatorPhase 1Apr 30, 2017
NCT01469273CollaboratorPhase 4Nov 1, 2011

Details

Last known activity: May 31, 2022